OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.
Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.
Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.
Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes research articles, reviews, communications and technical notes. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Archiving: full-text archived in CLOCKSS.
Publication Speed (median values for papers published in 2022): Submission to First Decision: 5 weeks; Submission to Acceptance: 14 weeks; Acceptance to Publication: 11 days (1-2 days of FREE language polishing included)
Geriatric Oncology: From Research to Clinical Practice
Submission Deadline: October 30, 2022 (Open) Submit Now
Giuseppe Ferdinando Colloca, MD, PhD, Professor
Gemelli ART – Cancer Center, Catholic University of Sacred Heart –Fondazione Policlinico A Gemelli IRCCS, Largo Francesco Vito 1, 00168 Rome Italy
Research Interests: Geriatric Oncology; Geriatric Syndrome; Pain Treatment; Geriatric Cardiology; Memory Deficiency; Palliative Care; Brachytherapy; Radiotherapy; Sarcopenia; Neoplasms; Elderly; Geriatric Assessment; Geriatrics; Thyroid Neoplasms
Manuscript Submission Information
Manuscripts should be submitted online at http://www.lidsen.com/Passport/Index/login by registering and logging in to this website. Once registered and activated, please click here to go to the submission form. A guide for authors and other relevant information for submission of manuscripts is available on Instructions for Authors.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are highly invited. For planned papers, a tentative title and short abstract (about 100 words) can be sent to the Editorial Office (email@example.com) for record. Welcome your submission!
by ANDREA BELLIENI , BEATRICE DI CAPUA , EMANUELE ROCCO VILLANI , LUCA TAGLIAFERRI , DOMENICO FUSCO , MARIA ANTONIETTA GAMBACORTA , FRANCESCO PRESTA , SERENA BRACCI , VINCENZO VALENTINI , FRANCESCO LANDI and GIUSEPPE FERDINANDO COLLOCA
Received: 17 November 2022; Published: 13 June 2023; doi: 10.21926/obm.geriatr.2302238
New technologies, aging-related changes, and evolution in patients' needs have led to a new scenario in all oncological fields in front of which we have to move on. Technological progress has made it possible to increase the number of patients treated, including elderly patients and generally those at higher risk of toxicity. Howev [...]
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.